Clinical Trial Update: In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis [Phase 2]

View source ↗

Summary

A Phase 2 trial of in vivo regulatory T cell expansion for prophylaxis of graft-versus-host disease has completed, with results posted in July 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Graft-Versus-Host-Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-07-02